CHO Pharma, Inc. (6586.TWO)

TWD 53.5

(0.38%)

Market Cap (In TWD)

11.44 Billion

Revenue (In TWD)

-

Net Income (In TWD)

-306.08 Million

Avg. Volume

265.23 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
49.0-72.3
PE
-
EPS
-
Beta Value
0.093
ISIN
TW0006586001
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Chung-Yi Wu Ph.D.
Employee Count
-
Website
https://www.chopharma.com
Ipo Date
2017-09-28
Details
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04, a humanized monoclonal antibody for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V08 for Klebsiella pneumonia. The company was founded in 2012 and is based in Taipei City, Taiwan.

More Stocks